Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c3c8dbc68a1bffd6400ab793b4e36ffc |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70532 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K11-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
filingDate |
2020-10-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30e581b557d787eec2b7721280bb2d43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0aad69d5411552283c453c7c1e72c6f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef3bd958b91f404033d56fb1c293bca3 |
publicationDate |
2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-114867753-A |
titleOfInvention |
heterotandem bicyclic peptide complex |
abstract |
The present invention relates to a heterotandem bicyclic peptide complex comprising a first peptide ligand that binds to a component present on cancer cells, the first peptide ligand being liganded through a linker to a second peptide that binds to a component present on immune cells body coupling. The present invention also relates to the use of the heterotandem bicyclic peptide complex in preventing, inhibiting or treating cancer. |
priorityDate |
2019-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |